🚨 Hims & Hers Stock Crashes 29% – Exclusive Charts & Market Analysis!
June 23, 2025
📈 Live Stock Charts
Hims & Hers (HIMS) plunged significantly from intraday highs, reflecting investor shock. Novo Nordisk (NVO) also slid, signaling broader market tremors in the GLP‑1 sector.
🔍 What Triggered the Crash?
- Partnership Withdrawal: Novo Nordisk terminated the high‑profile Wegovy collaboration amid compliance and safety concerns.
- Regulatory Shift: FDA cleared semaglutide from shortage status, ending legal exceptions for large‑scale compounding.
- Safety Red Flags: Allegations of unauthorized compound ingredients raised reputational and legal questions.
📊 Deep Financial Insights
Revenue for Hims & Hers surged—from approximately $272 M in 2021 to $1.5 B in 2024—driven in part by GLP‑1 offerings. Early 2025 showed continued year-over-year growth, though the loss of the Wegovy bundle could impact future momentum.
🕒 Key Market Timeline
- Feb 2025: FDA lifts semaglutide shortage, impacting compounding eligibility.
- Apr 29: Hims launches Wegovy bundle at $599/month—stock surges.
- Jun 23: Novo ends the deal—HIMS drops ~29%, NVO falls ~5–6%.
🌐 Strategic Impacts on Telehealth & Pharma
This dramatic shift highlights the tension between telehealth expansion and pharmaceutical regulation. Hims now needs to re‑strategize, potentially pivoting to mental health, dermatology, or international initiatives.
At the same time, major pharma players are tightening distribution controls post-shortage, reshaping the GLP‑1 competitive landscape.
